Med-tech giant Medtronic has agreed to pay $22 million to settle a lawsuit related to a controversial bone-growth product. The product, INFUSE, has been the target of of legal action but despite looming lawsuits and the recent settlement, Minneapolis-based Medtronic says it still stands behind the bone graft product.
According to the Wall Street Journal, some law firms have advised Medtronic that they may bring a large number of similar claims against the company in the future. The company estimates those law firms represent approximately 2,600 additional unfiled claimants. The majority of these cases are still in the early procedural stages and none have resulted in a finding of liability against Medtronic.